Drug intelligence / Profile preview

C29

Development stage: Preclinical
Modality: Small Molecules
Administration: Sublingual

Overview

C29 is a novel pharmacological inhibitor targeting CXCR1 and CXCR2 receptors. It has demonstrated anti-proliferation and anti-survival activity against various cancer cell lines, including those resistant to standard treatments like sunitinib and cisplatin. In preclinical studies, C29 reduced tumor growth, angiogenesis, and inflammation in mouse models of clear cell Renal Cell Carcinoma (RCC) and Head and Neck Squamous Cell Carcinoma (HNSCC). Its mechanism involves reducing ELR+CXCL/CXCR1/2-dependent proliferation and migration of endothelial cells.

Targets

CXCR2 (C-X-C Motif Chemokine Receptor 2)CXCR1 (C-X-C chemokine receptor 1)

Beyond the preview

Go deeper on C29.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C29.

Explore the full profile